Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | AXL | P30530 | 8/20 | 0.41 |
| ▸ | KDR | P35968 | 6/20 | 0.40 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.38 |
| ▸ | CDK4 | P11802 | 2/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | CCND1 | P24385 | 1/20 | 0.35 |
| ▸ | CCND2 | P30279 | 1/20 | 0.35 |
| ▸ | CCND3 | P30281 | 1/20 | 0.35 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4989938 | 1.00 | KDM4E (0.45) | KDM4EALDH1A1KMT2AMEN1PKM | |
| SCHEMBL11315406 | 0.84 | KDM4E (0.57) | KDM4EALDH1A1KMT2AMEN1PKM | |
| SCHEMBL13698447 | 0.84 | KDM4E (0.57) | KDM4EALDH1A1KMT2AMEN1PKM | |
| SCHEMBL17166950 | 0.84 | KDM4E (0.57) | KDM4EALDH1A1KMT2AMEN1PKM | |
| SCHEMBL14090630 | 0.82 | AXL (0.48) | KDM4EALDH1A1KMT2AMEN1PKM | |
| SCHEMBL12725510 | 0.82 | KMT2A (0.56) | KDM4EALDH1A1KMT2AMEN1PKM | |
| SCHEMBL11318463 | 0.82 | AXL (0.48) | KDM4EALDH1A1KMT2AMEN1PKM | |
| SCHEMBL15759153 | 0.82 | KMT2A (0.56) | KDM4EALDH1A1KMT2AMEN1PKM | |
| SCHEMBL3452912 | 0.82 | AXL (0.45) | KDM4EALDH1A1KMT2AMEN1PKM | |
| SCHEMBL3959773 | 0.82 | AXL (0.48) | KDM4EALDH1A1KMT2AMEN1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110551105-A | substituted triazoles useful as AXL inhibitors | RIGEL PHARMACEUTICALS INC | 2019-12-10 | — | — | CN | disclosed |
| US-10166216-B2 | Substituted triazoles useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2019-01-01 | — | — | US | disclosed |
| EP-2079736-B1 | SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2017-10-18 | — | — | EP | disclosed |
| US-20160243085-A1 | SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | MIDCAP FINANCIAL TRUST | 2016-08-25 | — | — | US | disclosed |
| US-9353126-B2 | Substituted triazoles useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| EP-2476679-B1 | Substituted triazoles useful as AXL inhibitors | RIGEL PHARMACEUTICALS INC (US) | 2015-10-14 | — | — | EP | disclosed |
| US-20150072959-A1 | SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | MIDCAP FINANCIAL TRUST | 2015-03-12 | — | — | US | disclosed |
| US-8906922-B2 | Substituted triazoles useful as AXl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| EP-2476679-A2 | Substituted triazoles useful as AXL inhibitors | Rigel Pharmaceuticals, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| US-20080188474-A1 | e.g. 1-phenyl-N3-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-1H-1,2,4-triazole-3,5-diamine; receptor protein tyrosine kinase (AXL) antagonist; antiinflammatory, anticarcinogenic , antidiabetic agent; rheumatoid arthritis, vascular disease; breast, renal, endometrial, ovarian carcinoma, or myeloid leukemia | RIGEL PHARMACEUTICALS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10166216-B2 | Substituted triazoles useful as Axl inhibitors | AXL, TYRO3, MERTK | KDM4E 4019/4885ALDH1A1 4309/4885KMT2A 2917/4885 |
| US-20150072959-A1 | SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, TYRO3, MERTK | KDM4E 4019/4885ALDH1A1 4309/4885KMT2A 2917/4885 |
| US-20160243085-A1 | SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, TYRO3, MERTK | KDM4E 4019/4885ALDH1A1 4309/4885KMT2A 2917/4885 |
| US-20080188474-A1 | e.g. 1-phenyl-N3-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-1H-1,2,4-triazole-3,5-diamine; receptor protein tyrosine kinase (AXL) antagonist; antiinflammatory, anticarcinogenic , antidiabetic agent; rheumatoid arthritis, vascular disease; breast, renal, endometrial, ovarian carcinoma, or myeloid leukemia | AXL, TYRO3, FLT3 | KDM4E 1183/4885ALDH1A1 2732/4885KMT2A 1602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.